Abstract
Post-transplant lymphoproliferative disease (PTLD) is a B cell proliferative disorder that is associated with Epstein-Barr virus (EBV), an ubiquitous herpesvirus. EBV-seronegative organ transplant recipients are at highest risk. EBV infection in PTLD lesions exists in a latent rather than lytic state, making tumor regression in response to antiviral agents unlikely. Viral latency proteins drive proliferation of T cells but also allow T cells to target PTLD lesions for destruction. Augmentation of the cellular immune response via the infusion of EBV-specific cytotoxic T cells has yielded promising results in the prevention and treatment of PTLD in bone marrow transplant recipients. Efforts to extend this strategy to solid organ transplant recipients are ongoing.
Original language | English (US) |
---|---|
Pages (from-to) | 204-212 |
Number of pages | 9 |
Journal | Transplant infectious disease : an official journal of the Transplantation Society |
Volume | 1 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1999 |
ASJC Scopus subject areas
- Infectious Diseases
- Transplantation